Skylight Therapeutics SRL
Skylight Therapeutics reported total assets of 21,284 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Skylight Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Skylight Therapeutics's annual accounts
| 2025 | |
|---|---|
| Net result | −57,733 € |
| Equity | −54,733 € |
| Cash | 935 € |
| EBITDA | −55,411 € |
| Total assets | 21,284 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
Skylight Therapeutics's financial analysis
- Solvency-257.2%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Skylight Therapeutics
Skylight Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1015.430.741
- VAT number
- BE1015430741
- Peppol
- Registered · 0208:1015430741 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Oct 2024
- Registered office
- 3001 Leuven
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Skylight Therapeutics (SRL) has been based in Leuven since 2024, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 57,733 € and equity of −54,733 €; its revenue is not published. Its solvency stands at -257.2%, below the median of its sector (60.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Skylight Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- CTTec Research and experimental development on natural sciences and engineering Menen · balance sheet 259,750 €
- Yagh Penn Consulting Research and experimental development on natural sciences and engineering Bertem · balance sheet 34,428 €
- Polyphemus Research and experimental development on natural sciences and engineering Watermael-Boitsfort · balance sheet 34,603 €
- Nuphar Tech Research and experimental development on natural sciences and engineering Koksijde · balance sheet 20,308 €
- PLT Bioconsult Research and experimental development on natural sciences and engineering Liège · balance sheet 32,499 €
- Swanet Biotech Research and experimental development on natural sciences and engineering Gembloux · balance sheet 26,578 €
- JN-RD Research and experimental development on natural sciences and engineering Oreye · balance sheet 67,834 €
- Plus Breeding Research and experimental development on natural sciences and engineering Lokeren · balance sheet 33,093 €
Frequently asked questions about Skylight Therapeutics
What is the revenue of Skylight Therapeutics?
Skylight Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Skylight Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE1015430741 for Skylight Therapeutics, if the company is VAT-registered. Its company number (CBE) is 1015.430.741.
Where is the registered office of Skylight Therapeutics?
According to the CBE register, the registered office of Skylight Therapeutics is in 3001 Leuven.
What is the equity of Skylight Therapeutics?
At the close of the 2025 financial year, the equity of Skylight Therapeutics amounts to -54,733 €, a solvency of -257.2% of total assets.
Who manages Skylight Therapeutics?
The register lists 1 active mandates at Skylight Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Skylight Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →